stonks4u
Sign up free
BTAI logo

BTAI BioXcel Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$1.19
+0.06 (+5.31%)

BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorith…

Market Cap: $36.74Mwww.bioxceltherapeutics.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
80
Aug 13Aug 13

Quote

Day Range
$1.01 – $1.23
52-Week Range
$0.74 – $6.85
Volume
$2.03M
Market Cap
$36.74M
50-Day Avg
$1.04
200-Day Avg
$1.44
Prev Close
$1.13
Open
$1.10

Valuation & Ratios

P/E Ratio
-0.28
EPS
$-5.73
P/B Ratio
-0.20
P/S Ratio
30.42
Debt/Equity
-1.15
Current Ratio
0.83
Dividend Yield
+0.0%
Gross Margin
+74.5%

Returns & Efficiency

Return on Equity
+73.2%
Return on Assets
-155.6%
FCF Yield
-295.0%
EV/EBITDA
-1.92

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$642.0K$-69.90M$-5.73
2024$2.27M$-59.60M$-23.51
2023$1.38M$-179.05M$-98.35
2022$375.0K$-165.76M$-94.67
2021$0.00$-106.93M$-64.87

Social Signal Score

30
5d
30
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $-0.63 per share

3of 7 quarters beat consensus

Typical surprise -6.5% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.49 vs $-0.44miss
  • Fri, May 15$-0.54 vs $-0.59beat
  • Thu, Mar 26$-0.58 vs $-0.34miss
  • Wed, Nov 12$-2.18 vs $-1.54miss
  • Tue, Aug 12$-2.45 vs $-2.30miss
  • Mon, May 12$-1.50 vs $-2.72beat

Estimates and results for BTAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

BTAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newszacks.com·1d ago·Negative

    BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $2.45 per share a year ago.

    View source ↗